Medicus Pharma reports 73% clearance rate in basal cell carcinoma trial
Tweet Send to a Friend
Medicus Pharma Ltd. (NASDAQ: MDCX) reported that its SkinJect microneedle delivery system achieved 73% clinical clearance in patients with basal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
